Senti Biosciences, INC 8-K filings

Senti Biosciences Holdings, Inc. announces a strategic merger with an affiliate of its largest stockholder, Celadon Partners, to spin off its Gene-Circuit pipeline, including SENTI-202, while retaining focus on Regulator Dial technology for future gene and cell therapies.

Senti Biosciences Holdings, Inc. announced the closing of a $10.0 million Senior Secured Convertible Note issuance to Celadon Partners SPV 24, with related agreements including a Guarantee and Voting Agreements.

Senti Biosciences reported Q1 2026 results, highlighting positive FDA feedback for SENTI-202 pivotal trial and a strategic financing agreement.

Senti Biosciences Holdings, Inc. announced a private placement of up to $40 million in senior secured convertible notes, with its largest stockholder, Celadon Partners, providing the initial $10 million.

Senti Biosciences, Inc. has completed its holding company reorganization, establishing Senti Biosciences Holdings, Inc. as the new public parent entity, with no material change to operations.

Senti Biosciences, Inc. announced plans for a tax-free holding company reorganization, converting existing shares into those of a new parent entity, Senti Biosciences Holdings, Inc., by April 16, 2026.

Senti Biosciences reported full year 2025 financial results, highlighting positive clinical data for SENTI-202 and its RMAT designation, alongside increased net losses and reduced cash reserves.

Senti Biosciences significantly reduced its leased research and development and laboratory space, amending its primary lease and a sublease agreement to optimize real estate costs.

Senti Biosciences announced positive initial Phase 1 clinical data for SENTI-202 in relapsed/refractory AML, achieving high response rates and a favorable safety profile, alongside an FDA RMAT designation.

Senti Biosciences announced its third-quarter 2025 financial results and confirmed an upcoming clinical data readout for its SENTI-202 study in AML at the American Society of Hematology Annual Meeting in December.

Senti Biosciences announced its second quarter 2025 financial results and confirmed the recommended Phase 2 dose for its lead oncology program, SENTI-202, with new data expected in Q4 2025.

Senti Biosciences, a clinical-stage biotechnology company, has appointed serial entrepreneur and venture capitalist Bryan Baum to its Board of Directors, expanding the board to eight members.

Senti Biosciences, Inc. announced that its stockholders elected three Class III directors and ratified KPMG LLP as its independent registered public accounting firm for the fiscal year ending December 31, 2025, at the 2025 Annual Meeting.

Senti Biosciences announced that its lead investigational therapy, SENTI-202, has been granted Orphan Drug Designation by the U.S. FDA for the treatment of relapsed/refractory hematologic malignancies, including Acute Myeloid Leukemia.

Senti Biosciences announces encouraging Phase 1 clinical trial results for SENTI-202 in AML and reports its first quarter 2025 financial results.

Senti Biosciences reports positive preliminary Phase 1 clinical trial data for SENTI-202, a novel CAR-NK cell therapy for relapsed/refractory AML, demonstrating promising efficacy and a manageable safety profile.

Senti Biosciences has filed a registration statement for up to $300 million in securities and entered into a sales agreement for an at-the-market offering of common stock through Leerink Partners.

Senti Biosciences reports promising early clinical trial results for SENTI-202 in AML patients and secures $47.6 million through a private investment.

Senti Biosciences expands its Board of Directors with the appointment of Feng Hsiung and increases the shares available under its equity incentive plan.

Senti Biosciences' stockholders approved an amended and restated 2022 Equity Incentive Plan at a special meeting on March 6, 2025.

Senti Biosciences strengthens its leadership team with the appointment of Jay Cross as CFO and Faraz Siddiqui as SVP of Technical Operations to drive strategic growth and optimize manufacturing.

Senti Biosciences' Interim CFO Yvonne Li's consulting agreement expired on January 31, 2025, and she will transition her responsibilities until March 31, 2025, under a new consulting agreement.

Senti Biosciences has secured an additional $10 million in private placement equity financing and $1.5 million from a CIRM grant, extending its cash runway into 2026.

Senti Biosciences has announced the first patient has been dosed in a clinical trial for SN301A, a CAR-NK cell therapy for hepatocellular carcinoma, in collaboration with Celest Therapeutics.

Senti Biosciences announced encouraging initial clinical data from its Phase 1 trial of SENTI-202, showing complete remission in two out of three relapsed/refractory AML patients at the first dose level.

Senti Biosciences has successfully raised $37.6 million through a private placement to advance its cell and gene therapy programs.

Senti Biosciences reports promising early results from a Phase 1 trial of SENTI-202, with two out of three AML patients achieving complete remission and MRD negativity at the first dose level.

Senti Biosciences reported its Q3 2024 financial results, highlighted by ongoing clinical trials for SENTI-202 and progress in its collaboration for SENTI-301A.

Senti Biosciences received a notice from Nasdaq for not complying with audit committee requirements due to a vacancy, and has until December 9, 2024, or their next annual meeting to regain compliance.

Senti Biosciences has entered into a sublease agreement for a portion of its corporate headquarters with BKPBIOTECH and JLSA2 Therapeutics, effective October 1, 2024.